Several lncRNAs have been reported to be highly expressed in ovarian cancer and promote cisplatin resistance, such as MCF2L-AS1, ACTA2-AS1, and CASC10,100, 101, 102, 103, 104, 105, 106, 107 while other lncRNAs have been found to increase cisplatin sensitivity of ovarian cancer cells, including CERNA1 and SLC25A21-AS1.108. This evidence concerns the gene ACTA2 and ovarian carcinoma.